You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
來凱醫藥-B(02105.HK):LAE102針對肥胖症治療的I期單劑量遞增研究(SAD研究)已成功完成
格隆匯 01-13 08:31

格隆匯1月13日丨來凱醫藥-B(02105.HK)發佈公吿,集團已成功完成了LAE102針對肥胖症治療的I期單劑量遞增研究(“SAD研究”)。SAD研究共招募了64名健康受試者,平均BMI 23.2±2.2 kg/m2,包括5個靜脈給藥隊列和3個皮下給藥隊列。SAD研究的結果為我們即將近期在中國進行的I期多次遞增劑量研究(“MAD研究”)以及與禮來公司(“禮來”)合作在美國進行的I期臨牀研究奠定了良好基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account